Readystate Asset Management’s Akero Therapeutics AKRO Stock Holding History

Readystate Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-237,908	Closed	-$11.3M	–	388
2025 Q3	$11.3M	Sell	237,908 -403,015	-63%	-$19.5M	0.48%	56
2025 Q2	$34.2M	Buy	640,923 +540,423	+538%	+$24.6M	1.05%	18
2025 Q1	$4.07M	Buy	+100,500	New	+$4.26M	0.14%	122

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Readystate Asset Management's AKRO Position: Q4 2025 in Review

Readystate Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 237,908 shares — an estimated $11.3M sold.

Readystate Asset Management first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $34.2M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Readystate Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Readystate Asset Management sold 237,908 Akero Therapeutics shares in Q4 2025, an estimated $11.3M.
Readystate Asset Management first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
Readystate Asset Management's Akero Therapeutics position peaked at $34.2M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Readystate Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.